Blueprint Bio, Inc., a Newport Beach, CA-based personalized medicine company, raised $7.5m in funding.
Forentis Partners‘s Forentis Fund, a $50m venture capital fund focused on biotechnology, has committed to provide the funding.
Founded in 2015, Blueprint Bio is creating a validated marketplace for biomarker signatures in personalized medicine. The company, which identifies, protects and offers new biological discoveries to existing clinical, pharmaceutical and diagnostic companies, has already filed patent applications in a variety of drug response solutions and oncology focused diagnostics. In order to de-risk and accelerate their biomarker discovery, it is collaborating with researchers and companies who are generating biologic patient data from mass spectrometers and gene sequencing machines, among other assay methods.
The company – which has additional offices at the University of Pennsylvania and the Mayo Clinic – is a co-founder of BluePen Biomarkers, an initiative that is creating a biomarker measurement and discovery pipeline for the acceleration of personalized medicine.
Matthew Nunez is the CEO of both Blueprint Bio and BluePen Biomarkers.
FinSMEs
20/06/2016